相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IL-20, IL-21 and p40: Potential Biomarkers of Treatment Response for Ustekinumab
Anne Gedebjerg et al.
ACTA DERMATO-VENEREOLOGICA (2013)
A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial
T. -F. Tsai et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C
H. -Y. Chiu et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab
M. Talamonti et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
The Role of Fcγ Receptor Polymorphisms in the Response to Anti-Tumor Necrosis Factor Therapy in Psoriasis A Pharmacogenetic Study
Marc Julia et al.
JAMA DERMATOLOGY (2013)
Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the UK and Ireland
P. M. Laws et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
T. -F. Tsai et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Long-term efficacy of ustekinumab in moderate-to-severe psoriasis
A. B. Kimball et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis
H. Y. Chiu et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy
H. L. Hebert et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
T helper type 17 in psoriasis: From basic immunology to clinical practice
Hsien-Yi Chiu et al.
DERMATOLOGICA SINICA (2012)
TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis
Trilokraj Tejasvi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Pharmacogenetic Analysis of TNF, TNFRSF1A, and TNFRSF1B Gene Polymorphisms and Prediction of Response to Anti-TNF Therapy in Psoriasis Patients in the Greek Population
Yiannis Vasilopoulos et al.
MOLECULAR DIAGNOSIS & THERAPY (2012)
Markers of Treatment Response toMethotrexate in Rheumatoid Arthritis: Where Do We Stand?
Karina I. Halilova et al.
INTERNATIONAL JOURNAL OF RHEUMATOLOGY (2012)
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial
M. Lebwohl et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis
Shunsuke Mori et al.
CLINICAL RHEUMATOLOGY (2010)
Molecular Dissection of Psoriasis: Integrating Genetics and Biology
James T. Elder et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations
Mark Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
The Latest Advances in Pharmacogenetics and Pharmacogenomics in the Treatment of Psoriasis
Caitriona Ryan et al.
MOLECULAR DIAGNOSIS & THERAPY (2010)
Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis
Pieter C. M. Res et al.
PLOS ONE (2010)
Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis
Yaowei Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
IL-23 Drives Pathogenic IL-17-Producing CD8(+) T Cells
Bogoljub Ciric et al.
JOURNAL OF IMMUNOLOGY (2009)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Fine mapping of the psoriasis susceptibility locus PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population
Xing Fan et al.
PLOS GENETICS (2008)
Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population
Xing Fan et al.
ACTA DERMATO-VENEREOLOGICA (2007)
Increased expression of the natural killer cell inhibitory receptor CD94/NKG2A and CD158b on circulating and lesional T cells in patients with chronic plaque psoriasis
Y. H. Liao et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients -: An analysis of 1019 HLA-C- and HLA-B-typed patients
Johann E. Gudjonsson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8+ T cells
A Johnston et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2004)
A study of candidate genes for psoriasis near HLA-C in Chinese patients with psoriasis
YT Chang et al.
BRITISH JOURNAL OF DERMATOLOGY (2003)
HLA-Cw6 specificity and polymorphic residues are associated with susceptibility among Chinese psoriatics in Taiwan
TF Tsai et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2002)
HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features
JE Gudjónsson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2002)
分享论文
